Trial Outcomes & Findings for Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease (NCT NCT00423085)
NCT ID: NCT00423085
Last Updated: 2014-02-10
Results Overview
The Alzheimer's Disease Assessment Scale - Japan cognitive subscale (ADAS-J cog) was used to measure change in cognitive function. The ADAS-J cog score ranges from 0-70, with higher total scores indicating more impairment. A negative change score indicates improvement from baseline.
Recruitment status
COMPLETED
Study phase
PHASE3
Target enrollment
859 participants
Primary outcome timeframe
Baseline and Week 24
Results posted on
2014-02-10
Participant Flow
Participants were randomly assigned in a double-blind manner to one of the 3 treatment arms (placebo, rivastigmine 5 cm\^2 and rivastigmine 10 cm\^2) in a ratio of 1:1:1. Following the 24-week double-blind treatment phase, participants could enroll in the open-label extension phase, where all participants were titrated up to the 10 cm\^2 patch dose.
Participant milestones
| Measure |
Placebo
Participants received daily matching placebo patch for the duration of the 24-week double-blind treatment phase of the study.
|
Rivastigmine 5 cm^2
During the 16-week titration period patients received daily rivastigmine 2.5 cm\^2 patch for the first 4 weeks and then daily rivastigmine 5 cm\^2 patch. For patients who experienced intolerability, the dose was adjusted to rivastigmine 2.5 cm\^2 daily. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
|
Rivastigmine 10 cm^2
During the 16-week titration period patients received daily rivastigmine 2.5 cm\^2 patch for the first 4 weeks, rivastigmine 5 cm\^2 for the next 4 weeks, rivastigmine 7.5 cm\^2 patch for the next 4 weeks and then rivastigmine 10 cm\^2 patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
|
Open-label Extension
All participants started treatment with daily rivastigmine 2.5 cm\^2 patch. The dose was increased to 5, 7.5, and 10 cm\^2 after 4 weeks of treatment at each dose level. One patch was applied once daily. The dose level reached by each individual patient at the end of this 16 weeks was maintained for the rest of the study duration (Maintenance Period). A predetermined "allowed adjustment" scheme was followed in patients who required dose adjustment due to low tolerability.
|
|---|---|---|---|---|
|
24-Week Double-Blind Treatment Phase
STARTED
|
288
|
284
|
287
|
0
|
|
24-Week Double-Blind Treatment Phase
COMPLETED
|
242
|
220
|
228
|
0
|
|
24-Week Double-Blind Treatment Phase
NOT COMPLETED
|
46
|
64
|
59
|
0
|
|
52-Week Open-Label Extension Phase
STARTED
|
0
|
0
|
0
|
637
|
|
52-Week Open-Label Extension Phase
COMPLETED
|
0
|
0
|
0
|
474
|
|
52-Week Open-Label Extension Phase
NOT COMPLETED
|
0
|
0
|
0
|
163
|
Reasons for withdrawal
| Measure |
Placebo
Participants received daily matching placebo patch for the duration of the 24-week double-blind treatment phase of the study.
|
Rivastigmine 5 cm^2
During the 16-week titration period patients received daily rivastigmine 2.5 cm\^2 patch for the first 4 weeks and then daily rivastigmine 5 cm\^2 patch. For patients who experienced intolerability, the dose was adjusted to rivastigmine 2.5 cm\^2 daily. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
|
Rivastigmine 10 cm^2
During the 16-week titration period patients received daily rivastigmine 2.5 cm\^2 patch for the first 4 weeks, rivastigmine 5 cm\^2 for the next 4 weeks, rivastigmine 7.5 cm\^2 patch for the next 4 weeks and then rivastigmine 10 cm\^2 patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
|
Open-label Extension
All participants started treatment with daily rivastigmine 2.5 cm\^2 patch. The dose was increased to 5, 7.5, and 10 cm\^2 after 4 weeks of treatment at each dose level. One patch was applied once daily. The dose level reached by each individual patient at the end of this 16 weeks was maintained for the rest of the study duration (Maintenance Period). A predetermined "allowed adjustment" scheme was followed in patients who required dose adjustment due to low tolerability.
|
|---|---|---|---|---|
|
24-Week Double-Blind Treatment Phase
Adverse Event
|
21
|
38
|
34
|
0
|
|
24-Week Double-Blind Treatment Phase
Withdrawal by Subject
|
8
|
16
|
11
|
0
|
|
24-Week Double-Blind Treatment Phase
Unsatisfactory therapeutic effect
|
7
|
6
|
7
|
0
|
|
24-Week Double-Blind Treatment Phase
Protocol Violation
|
8
|
3
|
7
|
0
|
|
24-Week Double-Blind Treatment Phase
Death
|
1
|
1
|
0
|
0
|
|
24-Week Double-Blind Treatment Phase
Lost to Follow-up
|
1
|
0
|
0
|
0
|
|
52-Week Open-Label Extension Phase
Adverse Event
|
0
|
0
|
0
|
97
|
|
52-Week Open-Label Extension Phase
Withdrawal by Subject
|
0
|
0
|
0
|
37
|
|
52-Week Open-Label Extension Phase
Unsatisfactory therapeutic effect
|
0
|
0
|
0
|
18
|
|
52-Week Open-Label Extension Phase
Protocol deviation
|
0
|
0
|
0
|
9
|
|
52-Week Open-Label Extension Phase
Death
|
0
|
0
|
0
|
2
|
Baseline Characteristics
Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease
Baseline characteristics by cohort
| Measure |
Placebo
n=286 Participants
Participants received daily matching placebo patch for the duration of the 24-week double-blind treatment phase of the study.
|
Rivastigmine 5 cm^2
n=282 Participants
During the 16-week titration period patients received daily rivastigmine 2.5 cm\^2 patch for the first 4 weeks and then daily rivastigmine 5 cm\^2 patch. For patients who experienced intolerability, the dose was adjusted to rivastigmine 2.5 cm\^2 daily. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
|
Rivastigmine 10 cm^2
n=287 Participants
During the 16-week titration period patients received daily rivastigmine 2.5 cm\^2 patch for the first 4 weeks, rivastigmine 5 cm\^2 for the next 4 weeks, rivastigmine 7.5 cm\^2 patch for the next 4 weeks and then rivastigmine 10 cm\^2 patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
|
Total
n=855 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Continuous
|
74.5 years
STANDARD_DEVIATION 7.36 • n=5 Participants
|
74.3 years
STANDARD_DEVIATION 7.46 • n=7 Participants
|
75.1 years
STANDARD_DEVIATION 6.85 • n=5 Participants
|
74.6 years
STANDARD_DEVIATION 7.22 • n=4 Participants
|
|
Sex: Female, Male
Female
|
195 Participants
n=5 Participants
|
194 Participants
n=7 Participants
|
195 Participants
n=5 Participants
|
584 Participants
n=4 Participants
|
|
Sex: Female, Male
Male
|
91 Participants
n=5 Participants
|
88 Participants
n=7 Participants
|
92 Participants
n=5 Participants
|
271 Participants
n=4 Participants
|
PRIMARY outcome
Timeframe: Baseline and Week 24Population: The Intent-to-treat population: This population includes all randomized patients who received at least one dose of study drug and had at least a baseline and any post-baseline assessment on treatment (i.e. not more than 2 days after the last known date of study drug) for one of the primary efficacy variables. LOCF was utilized.
The Alzheimer's Disease Assessment Scale - Japan cognitive subscale (ADAS-J cog) was used to measure change in cognitive function. The ADAS-J cog score ranges from 0-70, with higher total scores indicating more impairment. A negative change score indicates improvement from baseline.
Outcome measures
| Measure |
Placebo
n=265 Participants
Participants received daily matching placebo patch for the duration of the 24-week double-blind treatment phase of the study.
|
Rivastigmine 5 cm^2
n=266 Participants
During the 16-week titration period patients received daily rivastigmine 2.5 cm\^2 patch for the first 4 weeks and then daily rivastigmine 5 cm\^2 patch. For patients who experienced intolerability, the dose was adjusted to rivastigmine 2.5 cm\^2 daily. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
|
Rivastigmine 10 cm^2
n=268 Participants
During the 16-week titration period patients received daily rivastigmine 2.5 cm\^2 patch for the first 4 weeks, rivastigmine 5 cm\^2 for the next 4 weeks, rivastigmine 7.5 cm\^2 patch for the next 4 weeks and then rivastigmine 10 cm\^2 patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
|
|---|---|---|---|
|
Change From Baseline in the Alzheimer's Disease Assessment Scale - Japan Cognitive Subscale (ADAS-J Cog)
Baseline Score
|
24.8 units on a scale
Standard Deviation 9.46
|
25.2 units on a scale
Standard Deviation 9.62
|
25.0 units on a scale
Standard Deviation 9.93
|
|
Change From Baseline in the Alzheimer's Disease Assessment Scale - Japan Cognitive Subscale (ADAS-J Cog)
Week 24 Score
|
26.1 units on a scale
Standard Deviation 11.49
|
25.7 units on a scale
Standard Deviation 11.70
|
25.1 units on a scale
Standard Deviation 11.25
|
|
Change From Baseline in the Alzheimer's Disease Assessment Scale - Japan Cognitive Subscale (ADAS-J Cog)
Change from Baseline
|
1.3 units on a scale
Standard Deviation 5.07
|
0.5 units on a scale
Standard Deviation 4.96
|
0.1 units on a scale
Standard Deviation 5.04
|
PRIMARY outcome
Timeframe: Baseline and Week 24Population: Intent-to-treat population utilizing LOCF.
The overall clinical rating of change from baseline to week 24 measured by the 7-point CIBIC plus-J scale. The Clinician's Interview-Based Impression of Change plus Caregiver Input consists of 3 subscales: Disability Assessment of Dementia Scale, Behavioral Pathology in Alzheimer's Disease Rating Scale and Mental Function Impairment Scale, as well as the Clinician's Global Impression of Change (CGIC). Participants are scored according to the following: 1. Markedly improved 2. Moderately improved 3. Minimally improved 4. Unchanged 5. Minimally worse 6. Moderately worse 7. Markedly worse
Outcome measures
| Measure |
Placebo
n=267 Participants
Participants received daily matching placebo patch for the duration of the 24-week double-blind treatment phase of the study.
|
Rivastigmine 5 cm^2
n=269 Participants
During the 16-week titration period patients received daily rivastigmine 2.5 cm\^2 patch for the first 4 weeks and then daily rivastigmine 5 cm\^2 patch. For patients who experienced intolerability, the dose was adjusted to rivastigmine 2.5 cm\^2 daily. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
|
Rivastigmine 10 cm^2
n=270 Participants
During the 16-week titration period patients received daily rivastigmine 2.5 cm\^2 patch for the first 4 weeks, rivastigmine 5 cm\^2 for the next 4 weeks, rivastigmine 7.5 cm\^2 patch for the next 4 weeks and then rivastigmine 10 cm\^2 patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
|
|---|---|---|---|
|
Overall Clinical Rating of Change From Baseline to Week 24 Measured by the Clinician's Interview-Based Impression of Change Plus - Japan (CIBIC Plus-J)
Markedly improved
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Overall Clinical Rating of Change From Baseline to Week 24 Measured by the Clinician's Interview-Based Impression of Change Plus - Japan (CIBIC Plus-J)
Moderately improved
|
5 Participants
|
12 Participants
|
6 Participants
|
|
Overall Clinical Rating of Change From Baseline to Week 24 Measured by the Clinician's Interview-Based Impression of Change Plus - Japan (CIBIC Plus-J)
Minimally improved
|
36 Participants
|
45 Participants
|
53 Participants
|
|
Overall Clinical Rating of Change From Baseline to Week 24 Measured by the Clinician's Interview-Based Impression of Change Plus - Japan (CIBIC Plus-J)
Unchanged
|
111 Participants
|
109 Participants
|
109 Participants
|
|
Overall Clinical Rating of Change From Baseline to Week 24 Measured by the Clinician's Interview-Based Impression of Change Plus - Japan (CIBIC Plus-J)
Minimally worse
|
84 Participants
|
82 Participants
|
78 Participants
|
|
Overall Clinical Rating of Change From Baseline to Week 24 Measured by the Clinician's Interview-Based Impression of Change Plus - Japan (CIBIC Plus-J)
Moderately worse
|
29 Participants
|
21 Participants
|
22 Participants
|
|
Overall Clinical Rating of Change From Baseline to Week 24 Measured by the Clinician's Interview-Based Impression of Change Plus - Japan (CIBIC Plus-J)
Markedly worse
|
2 Participants
|
0 Participants
|
2 Participants
|
SECONDARY outcome
Timeframe: Baseline and Week 24Population: Intent-to-treat population. Only patients with a valid baseline and post-baseline score were included.
The Disability Assessment for Dementia (DAD) was used to assess levels of difficulty in activities of daily living (ADL). The DAD is administered through an interview with the caregiver. A total score is obtained by adding the rating for each question and converting this to a total score out of 100 (%). Higher scores represent less disability in ADL while lower scores indicate more dysfunction. A positive change score indicates an improvement from baseline.
Outcome measures
| Measure |
Placebo
n=267 Participants
Participants received daily matching placebo patch for the duration of the 24-week double-blind treatment phase of the study.
|
Rivastigmine 5 cm^2
n=269 Participants
During the 16-week titration period patients received daily rivastigmine 2.5 cm\^2 patch for the first 4 weeks and then daily rivastigmine 5 cm\^2 patch. For patients who experienced intolerability, the dose was adjusted to rivastigmine 2.5 cm\^2 daily. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
|
Rivastigmine 10 cm^2
n=269 Participants
During the 16-week titration period patients received daily rivastigmine 2.5 cm\^2 patch for the first 4 weeks, rivastigmine 5 cm\^2 for the next 4 weeks, rivastigmine 7.5 cm\^2 patch for the next 4 weeks and then rivastigmine 10 cm\^2 patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
|
|---|---|---|---|
|
Change From Baseline in CIBIC Plus-J Score Disability Assessment for Dementia (DAD)
Baseline Score
|
66.70 units on a scale
Standard Deviation 19.902
|
64.19 units on a scale
Standard Deviation 20.571
|
64.15 units on a scale
Standard Deviation 21.921
|
|
Change From Baseline in CIBIC Plus-J Score Disability Assessment for Dementia (DAD)
Week 24 Score
|
62.54 units on a scale
Standard Deviation 22.395
|
61.19 units on a scale
Standard Deviation 22.415
|
62.27 units on a scale
Standard Deviation 23.691
|
|
Change From Baseline in CIBIC Plus-J Score Disability Assessment for Dementia (DAD)
Change from Baseline
|
-4.16 units on a scale
Standard Deviation 12.443
|
-2.99 units on a scale
Standard Deviation 10.259
|
-1.88 units on a scale
Standard Deviation 10.657
|
SECONDARY outcome
Timeframe: Baseline and Week 24Population: Intent-to-treat population. Only patients with a valid baseline and post-baseline score were included.
BEHAVE-AD was used to assess patient behavior and psychiatric symptoms. It covers symptoms in seven categories: paranoid and delusional ideation, hallucinations, activity disturbances, diurnal rhythm disturbances, aggressiveness, affective disorders and anxieties, and phobias. Caregivers rate behavioral symptoms on a 0-3 scale. The total score can range from 0 to 66, with a lower score indicating better function. A negative change score indicates an improvement from baseline.
Outcome measures
| Measure |
Placebo
n=267 Participants
Participants received daily matching placebo patch for the duration of the 24-week double-blind treatment phase of the study.
|
Rivastigmine 5 cm^2
n=269 Participants
During the 16-week titration period patients received daily rivastigmine 2.5 cm\^2 patch for the first 4 weeks and then daily rivastigmine 5 cm\^2 patch. For patients who experienced intolerability, the dose was adjusted to rivastigmine 2.5 cm\^2 daily. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
|
Rivastigmine 10 cm^2
n=270 Participants
During the 16-week titration period patients received daily rivastigmine 2.5 cm\^2 patch for the first 4 weeks, rivastigmine 5 cm\^2 for the next 4 weeks, rivastigmine 7.5 cm\^2 patch for the next 4 weeks and then rivastigmine 10 cm\^2 patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
|
|---|---|---|---|
|
Change From Baseline in CIBIC Plus-J Score Behavioral Pathology in Alzheimer's Disease Rating Scale (Behave-AD)
Week 24 Score
|
4.8 units on a scale
Standard Deviation 5.41
|
4.6 units on a scale
Standard Deviation 5.03
|
5.1 units on a scale
Standard Deviation 5.89
|
|
Change From Baseline in CIBIC Plus-J Score Behavioral Pathology in Alzheimer's Disease Rating Scale (Behave-AD)
Baseline Score
|
4.8 units on a scale
Standard Deviation 4.50
|
4.7 units on a scale
Standard Deviation 4.96
|
5.4 units on a scale
Standard Deviation 5.15
|
|
Change From Baseline in CIBIC Plus-J Score Behavioral Pathology in Alzheimer's Disease Rating Scale (Behave-AD)
Change from Baseline
|
-0.1 units on a scale
Standard Deviation 3.76
|
-0.1 units on a scale
Standard Deviation 4.17
|
-0.3 units on a scale
Standard Deviation 4.70
|
SECONDARY outcome
Timeframe: Baseline and Week 24Population: Intent-to-treat population. Only patients with a valid baseline and post-baseline score were included.
MENFIS was used to assess patient cognitive and psychiatric function, and evaluates core symptoms of dementia including cognitive, motivational and emotional aspects. The total score ranges from 0 to 78. The higher the score, the greater the functional deficit. A negative change score indicates an improvement from baseline.
Outcome measures
| Measure |
Placebo
n=267 Participants
Participants received daily matching placebo patch for the duration of the 24-week double-blind treatment phase of the study.
|
Rivastigmine 5 cm^2
n=269 Participants
During the 16-week titration period patients received daily rivastigmine 2.5 cm\^2 patch for the first 4 weeks and then daily rivastigmine 5 cm\^2 patch. For patients who experienced intolerability, the dose was adjusted to rivastigmine 2.5 cm\^2 daily. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
|
Rivastigmine 10 cm^2
n=270 Participants
During the 16-week titration period patients received daily rivastigmine 2.5 cm\^2 patch for the first 4 weeks, rivastigmine 5 cm\^2 for the next 4 weeks, rivastigmine 7.5 cm\^2 patch for the next 4 weeks and then rivastigmine 10 cm\^2 patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
|
|---|---|---|---|
|
Change From Baseline in CIBIC Plus-J Score Mental Function Impairment Scale (MENFIS)
Baseline Score
|
23.2 units on a scale
Standard Deviation 11.13
|
24.3 units on a scale
Standard Deviation 11.72
|
24.6 units on a scale
Standard Deviation 11.36
|
|
Change From Baseline in CIBIC Plus-J Score Mental Function Impairment Scale (MENFIS)
Week 24 Score
|
26.1 units on a scale
Standard Deviation 12.68
|
26.5 units on a scale
Standard Deviation 13.43
|
26.2 units on a scale
Standard Deviation 12.69
|
|
Change From Baseline in CIBIC Plus-J Score Mental Function Impairment Scale (MENFIS)
Change from Baseline
|
2.9 units on a scale
Standard Deviation 6.18
|
2.2 units on a scale
Standard Deviation 5.86
|
1.6 units on a scale
Standard Deviation 5.82
|
SECONDARY outcome
Timeframe: Baseline and Week 24Population: Intent-to-treat population. Only patients with a valid baseline and post-baseline score were included.
The MMSE is a screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language); the total score can range from 0 to 30, with a higher score indicating better function. A positive change score indicates improvement from baseline.
Outcome measures
| Measure |
Placebo
n=251 Participants
Participants received daily matching placebo patch for the duration of the 24-week double-blind treatment phase of the study.
|
Rivastigmine 5 cm^2
n=236 Participants
During the 16-week titration period patients received daily rivastigmine 2.5 cm\^2 patch for the first 4 weeks and then daily rivastigmine 5 cm\^2 patch. For patients who experienced intolerability, the dose was adjusted to rivastigmine 2.5 cm\^2 daily. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
|
Rivastigmine 10 cm^2
n=246 Participants
During the 16-week titration period patients received daily rivastigmine 2.5 cm\^2 patch for the first 4 weeks, rivastigmine 5 cm\^2 for the next 4 weeks, rivastigmine 7.5 cm\^2 patch for the next 4 weeks and then rivastigmine 10 cm\^2 patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
|
|---|---|---|---|
|
Change From Baseline in Mini-Mental State Examination (MMSE)
Baseline Score
|
16.7 units on a scale
Standard Deviation 2.87
|
16.9 units on a scale
Standard Deviation 2.88
|
16.4 units on a scale
Standard Deviation 3.09
|
|
Change From Baseline in Mini-Mental State Examination (MMSE)
Week 24 Score
|
16.4 units on a scale
Standard Deviation 4.21
|
16.6 units on a scale
Standard Deviation 4.62
|
16.4 units on a scale
Standard Deviation 4.47
|
|
Change From Baseline in Mini-Mental State Examination (MMSE)
Change from Baseline
|
-0.3 units on a scale
Standard Deviation 2.82
|
-0.3 units on a scale
Standard Deviation 3.05
|
0.0 units on a scale
Standard Deviation 2.87
|
SECONDARY outcome
Timeframe: Extension Phase Baseline and Week 52 of extension phasePopulation: Intent-to-treat population utilizing last observation carried forward. This population includes all patients who received at least one dose of open-label study medication and had at least one efficacy assessment on treatment in the open-label extension Phase.
The MMSE is a screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language); the total score can range from 0 to 30, with a higher score indicating better function. A positive change score indicates improvement. This outcome measured the change in MMSE from the beginning of the open-label extension phase through to Week 52 of the extension phase.
Outcome measures
| Measure |
Placebo
n=577 Participants
Participants received daily matching placebo patch for the duration of the 24-week double-blind treatment phase of the study.
|
Rivastigmine 5 cm^2
During the 16-week titration period patients received daily rivastigmine 2.5 cm\^2 patch for the first 4 weeks and then daily rivastigmine 5 cm\^2 patch. For patients who experienced intolerability, the dose was adjusted to rivastigmine 2.5 cm\^2 daily. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
|
Rivastigmine 10 cm^2
During the 16-week titration period patients received daily rivastigmine 2.5 cm\^2 patch for the first 4 weeks, rivastigmine 5 cm\^2 for the next 4 weeks, rivastigmine 7.5 cm\^2 patch for the next 4 weeks and then rivastigmine 10 cm\^2 patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
|
|---|---|---|---|
|
Extension Phase: Change From Extension Phase Baseline to End of Extension in Mini-Mental State Examination (MMSE)
Extension Baseline
|
16.6 units on a scale
Standard Deviation 4.43
|
—
|
—
|
|
Extension Phase: Change From Extension Phase Baseline to End of Extension in Mini-Mental State Examination (MMSE)
End of Extension
|
14.9 units on a scale
Standard Deviation 5.58
|
—
|
—
|
|
Extension Phase: Change From Extension Phase Baseline to End of Extension in Mini-Mental State Examination (MMSE)
Change from Baseline
|
-1.7 units on a scale
Standard Deviation 3.28
|
—
|
—
|
SECONDARY outcome
Timeframe: Extension Phase Baseline and Week 52 of extension phasePopulation: Intent-to-treat population utilizing last observation carried forward.
The Disability Assessment for Dementia (DAD) was used to assess levels of difficulty in activities of daily living. The DAD is administered through an interview with the caregiver. A total score is obtained by adding the rating for each question and converting this to a total score out of 100 (%). Higher scores represent less disability in activities of daily living while lower scores indicate more dysfunction. A positive change score indicates an improvement from baseline.
Outcome measures
| Measure |
Placebo
n=567 Participants
Participants received daily matching placebo patch for the duration of the 24-week double-blind treatment phase of the study.
|
Rivastigmine 5 cm^2
During the 16-week titration period patients received daily rivastigmine 2.5 cm\^2 patch for the first 4 weeks and then daily rivastigmine 5 cm\^2 patch. For patients who experienced intolerability, the dose was adjusted to rivastigmine 2.5 cm\^2 daily. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
|
Rivastigmine 10 cm^2
During the 16-week titration period patients received daily rivastigmine 2.5 cm\^2 patch for the first 4 weeks, rivastigmine 5 cm\^2 for the next 4 weeks, rivastigmine 7.5 cm\^2 patch for the next 4 weeks and then rivastigmine 10 cm\^2 patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
|
|---|---|---|---|
|
Extension Phase: Change From Extension Phase Baseline to End of Extension in CIBIC Plus-J Score Disability Assessment for Dementia (DAD)
Extension Baseline
|
61.99 units on a scale
Standard Deviation 22.939
|
—
|
—
|
|
Extension Phase: Change From Extension Phase Baseline to End of Extension in CIBIC Plus-J Score Disability Assessment for Dementia (DAD)
End of Extension
|
51.95 units on a scale
Standard Deviation 25.407
|
—
|
—
|
|
Extension Phase: Change From Extension Phase Baseline to End of Extension in CIBIC Plus-J Score Disability Assessment for Dementia (DAD)
Change from Baseline
|
-10.04 units on a scale
Standard Deviation 14.089
|
—
|
—
|
SECONDARY outcome
Timeframe: Extension Phase Baseline and Week 52 of extension phasePopulation: Intent-to-treat population utilizing last observation carried forward.
The Modified Crichton Scale includes a total of seven items evaluated in eight grades that assess basic activities of daily living, communication functions, psychiatric symptoms and quality of life; the total score can range from 0 to 56, with a lower score indicating better function. A negative change score indicates an improvement from baseline.
Outcome measures
| Measure |
Placebo
n=634 Participants
Participants received daily matching placebo patch for the duration of the 24-week double-blind treatment phase of the study.
|
Rivastigmine 5 cm^2
During the 16-week titration period patients received daily rivastigmine 2.5 cm\^2 patch for the first 4 weeks and then daily rivastigmine 5 cm\^2 patch. For patients who experienced intolerability, the dose was adjusted to rivastigmine 2.5 cm\^2 daily. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
|
Rivastigmine 10 cm^2
During the 16-week titration period patients received daily rivastigmine 2.5 cm\^2 patch for the first 4 weeks, rivastigmine 5 cm\^2 for the next 4 weeks, rivastigmine 7.5 cm\^2 patch for the next 4 weeks and then rivastigmine 10 cm\^2 patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
|
|---|---|---|---|
|
Extension Phase: Change From Extension Phase Baseline to End of Extension in Modified Crichton Scale
Extension Baseline
|
20.0 units on a scale
Standard Deviation 10.04
|
—
|
—
|
|
Extension Phase: Change From Extension Phase Baseline to End of Extension in Modified Crichton Scale
End of Extension
|
24.0 units on a scale
Standard Deviation 11.30
|
—
|
—
|
|
Extension Phase: Change From Extension Phase Baseline to End of Extension in Modified Crichton Scale
Change from Baseline
|
4.0 units on a scale
Standard Deviation 6.74
|
—
|
—
|
Adverse Events
Placebo (24 Weeks)
Serious events: 20 serious events
Other events: 157 other events
Deaths: 0 deaths
Rivastigmine 5 cm^2 (24 Weeks)
Serious events: 14 serious events
Other events: 206 other events
Deaths: 0 deaths
Rivastigmine 10 cm^2 (24 Weeks)
Serious events: 18 serious events
Other events: 214 other events
Deaths: 0 deaths
Open-Label Extension (52 Weeks)
Serious events: 74 serious events
Other events: 491 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
Placebo (24 Weeks)
n=286 participants at risk
Participants received daily matching placebo patch for the duration of the 24-week double-blind treatment phase of the study.
|
Rivastigmine 5 cm^2 (24 Weeks)
n=282 participants at risk
During the 16-week titration period patients received daily rivastigmine 2.5 cm\^2 patch for the first 4 weeks and thereafter daily rivastigmine 5 cm\^2 patch. For patients who experienced intolerability, the dose was adjusted to rivastigmine 2.5 cm\^2 daily. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
|
Rivastigmine 10 cm^2 (24 Weeks)
n=287 participants at risk
During the 16-week titration period patients received daily rivastigmine 2.5 cm\^2 patch for the first 4 weeks, rivastigmine 5 cm\^2 patch for the next 4 weeks, rivastigmine 7.5 cm\^2 patch for the next 4 weeks and then rivastigmine 10 cm\^2 patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
|
Open-Label Extension (52 Weeks)
n=637 participants at risk
All participants started treatment with daily rivastigmine 2.5 cm\^2 patch. The dose was increased to 5, 7.5, and 10 cm\^2 after 4 weeks of treatment at each dose level. One patch was applied once daily. The dose level reached by each individual patient at the end of this 16 weeks was maintained for the rest of the study duration (Maintenance Period). A predetermined "allowed adjustment" scheme was followed in patients who required dose adjustment due to low tolerability.
|
|---|---|---|---|---|
|
Injury, poisoning and procedural complications
Femoral neck fracture
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.35%
1/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.70%
2/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.94%
6/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Cardiac disorders
Acute myocardial infarction
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.47%
3/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Cardiac disorders
Angina pectoris
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Cardiac disorders
Angina unstable
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.35%
1/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Cardiac disorders
Bradycardia
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Cardiac disorders
Cardiac failure
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.35%
1/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Cardiac disorders
Myocardial infarction
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Ear and labyrinth disorders
Vertigo positional
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.35%
1/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Gastrointestinal disorders
Food poisoning
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Gastrointestinal disorders
Gastric polyps
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Gastrointestinal disorders
Gastric ulcer
|
0.35%
1/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Gastrointestinal disorders
Gastric ulcer haemorrhage
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Gastrointestinal disorders
Ileus
|
0.70%
2/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Gastrointestinal disorders
Inguinal hernia
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.47%
3/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Gastrointestinal disorders
Reflux oesophagitis
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Gastrointestinal disorders
Subileus
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.31%
2/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
General disorders
Condition aggravated
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.35%
1/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
General disorders
Hypothermia
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
General disorders
Pain
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Hepatobiliary disorders
Bile duct stone
|
0.35%
1/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Hepatobiliary disorders
Cholelithiasis
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Infections and infestations
Appendicitis
|
0.35%
1/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Infections and infestations
Bacteraemia
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Infections and infestations
Bronchiectasis
|
0.35%
1/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Infections and infestations
Bronchitis
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.31%
2/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Infections and infestations
Cellulitis
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.35%
1/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Infections and infestations
Cholangitis suppurative
|
0.35%
1/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Infections and infestations
Empyema
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Infections and infestations
Endocarditis
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Infections and infestations
Gastroenteritis
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.35%
1/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.31%
2/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Infections and infestations
Herpes zoster
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Infections and infestations
Pneumonia
|
0.70%
2/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.35%
1/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.70%
2/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.94%
6/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Infections and infestations
Upper respiratory tract infection
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Injury, poisoning and procedural complications
Contusion
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Injury, poisoning and procedural complications
Femur fracture
|
0.70%
2/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.35%
1/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Injury, poisoning and procedural complications
Fractured sacrum
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Injury, poisoning and procedural complications
Head injury
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Injury, poisoning and procedural complications
Heat stroke
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.35%
1/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Injury, poisoning and procedural complications
Humerus fracture
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Injury, poisoning and procedural complications
Lumbar vertebral fracture
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Injury, poisoning and procedural complications
Near drowning
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Injury, poisoning and procedural complications
Pelvic fracture
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Injury, poisoning and procedural complications
Radius fracture
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.31%
2/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Injury, poisoning and procedural complications
Scapula fracture
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Injury, poisoning and procedural complications
Skeletal injury
|
0.35%
1/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Injury, poisoning and procedural complications
Spinal compression fracture
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Injury, poisoning and procedural complications
Subdural haematoma
|
0.35%
1/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.47%
3/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Injury, poisoning and procedural complications
Tendon rupture
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.35%
1/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Injury, poisoning and procedural complications
Traumatic brain injury
|
0.35%
1/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Injury, poisoning and procedural complications
Ulna fracture
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Injury, poisoning and procedural complications
Upper limb fracture
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.35%
1/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Injury, poisoning and procedural complications
Vertebral injury
|
0.35%
1/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Investigations
Alanine aminotransferase increased
|
0.70%
2/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Investigations
Aspartate aminotransferase increased
|
0.70%
2/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Investigations
Blood lactate dehydrogenase increased
|
0.35%
1/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Investigations
Blood pressure increased
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Investigations
Electrocardiogram T wave inversion
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Investigations
Gamma-glutamyltransferase increased
|
0.35%
1/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Metabolism and nutrition disorders
Diabetes mellitus
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.35%
1/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Musculoskeletal and connective tissue disorders
Fracture delayed union
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.35%
1/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Musculoskeletal and connective tissue disorders
Lumbar spinal stenosis
|
0.35%
1/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.35%
1/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Musculoskeletal and connective tissue disorders
Osteoarthritis
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Musculoskeletal and connective tissue disorders
Pseudarthrosis
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.35%
1/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Musculoskeletal and connective tissue disorders
Spinal osteoarthritis
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.31%
2/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bone cancer metastatic
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer
|
0.35%
1/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastric cancer
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Inflammatory carcinoma of the breast
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Large intestine carcinoma
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic neoplasm
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal cancer
|
0.35%
1/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Transitional cell carcinoma
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Nervous system disorders
Brain stem haemorrhage
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Nervous system disorders
Cerebral haemorrhage
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.35%
1/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.35%
1/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Nervous system disorders
Cerebral infarction
|
0.35%
1/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.71%
2/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.70%
2/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.31%
2/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Nervous system disorders
Convulsion
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.35%
1/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Nervous system disorders
Dementia Alzheimer's type
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.35%
1/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Nervous system disorders
Epilepsy
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Nervous system disorders
Loss of consciousness
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.70%
2/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Nervous system disorders
Subarachnoid haemorrhage
|
0.35%
1/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Psychiatric disorders
Behavioural and psychiatric symptoms of dementia
|
0.35%
1/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Renal and urinary disorders
Calculus ureteric
|
0.35%
1/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Reproductive system and breast disorders
Prostatitis
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Respiratory, thoracic and mediastinal disorders
Asthma
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.31%
2/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Respiratory, thoracic and mediastinal disorders
Interstitial lung disease
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.35%
1/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.35%
1/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonia aspiration
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.35%
1/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.31%
2/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumothorax
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Vascular disorders
Embolism
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Vascular disorders
Hypertension
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.35%
1/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Vascular disorders
Varicose vein
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.35%
1/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Vascular disorders
Venous thrombosis
|
0.00%
0/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.16%
1/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
Other adverse events
| Measure |
Placebo (24 Weeks)
n=286 participants at risk
Participants received daily matching placebo patch for the duration of the 24-week double-blind treatment phase of the study.
|
Rivastigmine 5 cm^2 (24 Weeks)
n=282 participants at risk
During the 16-week titration period patients received daily rivastigmine 2.5 cm\^2 patch for the first 4 weeks and thereafter daily rivastigmine 5 cm\^2 patch. For patients who experienced intolerability, the dose was adjusted to rivastigmine 2.5 cm\^2 daily. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
|
Rivastigmine 10 cm^2 (24 Weeks)
n=287 participants at risk
During the 16-week titration period patients received daily rivastigmine 2.5 cm\^2 patch for the first 4 weeks, rivastigmine 5 cm\^2 patch for the next 4 weeks, rivastigmine 7.5 cm\^2 patch for the next 4 weeks and then rivastigmine 10 cm\^2 patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
|
Open-Label Extension (52 Weeks)
n=637 participants at risk
All participants started treatment with daily rivastigmine 2.5 cm\^2 patch. The dose was increased to 5, 7.5, and 10 cm\^2 after 4 weeks of treatment at each dose level. One patch was applied once daily. The dose level reached by each individual patient at the end of this 16 weeks was maintained for the rest of the study duration (Maintenance Period). A predetermined "allowed adjustment" scheme was followed in patients who required dose adjustment due to low tolerability.
|
|---|---|---|---|---|
|
Gastrointestinal disorders
Constipation
|
4.2%
12/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
2.1%
6/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
2.1%
6/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
6.8%
43/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Gastrointestinal disorders
Diarrhoea
|
2.4%
7/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
3.9%
11/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
3.1%
9/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
5.2%
33/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Gastrointestinal disorders
Nausea
|
3.1%
9/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
1.1%
3/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
7.0%
20/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
6.3%
40/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Gastrointestinal disorders
Vomiting
|
3.8%
11/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
3.9%
11/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
8.0%
23/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
9.1%
58/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
General disorders
Application site erythema
|
19.2%
55/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
37.6%
106/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
39.4%
113/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
34.5%
220/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
General disorders
Application site oedema
|
2.4%
7/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
12.4%
35/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
10.8%
31/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
10.0%
64/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
General disorders
Application site pruritus
|
21.3%
61/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
32.6%
92/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
34.8%
100/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
31.6%
201/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Infections and infestations
Nasopharyngitis
|
11.2%
32/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
7.8%
22/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
11.5%
33/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
14.9%
95/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Injury, poisoning and procedural complications
Contusion
|
2.1%
6/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
3.2%
9/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
2.8%
8/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
6.1%
39/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Investigations
Weight decreased
|
1.4%
4/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
2.5%
7/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
3.5%
10/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
5.5%
35/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.70%
2/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
0.00%
0/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
1.7%
5/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
5.0%
32/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
|
Skin and subcutaneous tissue disorders
Dermatitis contact
|
14.0%
40/286 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
24.5%
69/282 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
23.7%
68/287 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
25.4%
162/637 • Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.
Data presented in the Placebo, Rivastigmine 5 cm\^2 and Rivastigmine 10 cm\^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.
|
Additional Information
Study Director
Novartis Pharmaceuticals
Phone: 862-778-8300
Results disclosure agreements
- Principal investigator is a sponsor employee The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.
- Publication restrictions are in place
Restriction type: OTHER